Related references
Note: Only part of the references are listed.A systematic review and meta-analysis of cross-reactivity of antibodies induced by H7 influenza vaccine
Xiaoqin Gou et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2020)
Narcolepsy and 2009 H1N1 pandemic vaccination in Taiwan
Wan-Ting Huang et al.
SLEEP MEDICINE (2020)
Use of adjuvanted trivalent influenza vaccine in older-age adults: a systematic review of economic evidence
Ilaria Loperto et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2019)
Influenza syndromic surveillance and vaccine efficacy in the UK Armed Forces, 2017-2018
Mark Andrew Dermont et al.
JOURNAL OF THE ROYAL ARMY MEDICAL CORPS (2019)
Safety and Immunogenicity of MF59-Adjuvanted Cell Culture-Derived A/H5N1 Subunit Influenza Virus Vaccine: Dose-Finding Clinical Trials in Adults and the Elderly
Sharon E. Frey et al.
OPEN FORUM INFECTIOUS DISEASES (2019)
Effective Immunization of Older Adults Against Seasonal Influenza
William Schaffner et al.
AMERICAN JOURNAL OF MEDICINE (2018)
Adjuvant strategies to improve vaccination of the elderly population
Birgit Weinberger
CURRENT OPINION IN PHARMACOLOGY (2018)
Correlates of adjuvanticity: A review on adjuvants in licensed vaccines
Giuseppe Del Giudice et al.
SEMINARS IN IMMUNOLOGY (2018)
Influenza vaccine effectiveness in older adults compared with younger adults over five seasons
Kate Russell et al.
VACCINE (2018)
Immunology and efficacy of MF59-adjuvanted vaccines
Eun-Ju Ko et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2018)
Heterologous Two-Dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-Lasting Cellular Immunity to Influenza Virus A in Healthy Adults
L. Coughlan et al.
EBIOMEDICINE (2018)
Seasonal influenza immunisation: Strategies for older adults
William Schaffner et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2018)
Immunogenicity and safety of MF59-adjuvanted and full-dose unadjuvanted trivalent inactivated influenza vaccines among vaccine-naive children in a randomized clinical trial in rural Senegal
Aldiouma Diallo et al.
VACCINE (2018)
Safety and immunogenicity of an inactivated cell culture-derived H7N9 influenza vaccine in healthy adults: A phase I/II, prospective, randomized, open-label trial
Un-In Wu et al.
VACCINE (2017)
Two Doses of Inactivated Influenza Vaccine Improve Immune Response in Solid Organ Transplant Recipients: Results of TRANSGRIPE 1-2, a Randomized Controlled Clinical Trial
Elisa Cordero et al.
CLINICAL INFECTIOUS DISEASES (2017)
Evaluation of the Safety and Immunogenicity of a Candidate Pandemic Live Attenuated Influenza Vaccine (pLAIV) Against Influenza A(H7N9)
Mahdee Sobhanie et al.
JOURNAL OF INFECTIOUS DISEASES (2016)
Immunogenicity and Safety of Pandemic Influenza H5N1 Vaccines in Healthy Adults through Meta-Analysis
Qi Guo et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2016)
Immunogenicity of Avian Influenza A/Anhui/01/2005(H5N1) Vaccine With MF59 Adjuvant A Randomized Clinical Trial
Robert B. Belshe et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Serological Responses to an Avian Influenza A/H7N9 Vaccine Mixed at the Point-of-Use With MF59 Adjuvant A Randomized Clinical Trial
Mark J. Mulligan et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Evaluation of safety and immunogenicity of HNVAC, an MDCK-based H1N1 pandemic influenza vaccine, in Phase I single centre and Phase II/III multi-centre, double-blind, randomized, placebo-controlled, parallel assignment studies
V. H. Basavaraj et al.
VACCINE (2014)
Safety, Reactogenicity, and Immunogenicity of Inactivated Monovalent Influenza A(H5N1) Virus Vaccine Administered With or Without AS03 Adjuvant
Wilbur H. Chen et al.
OPEN FORUM INFECTIOUS DISEASES (2014)
Selection of an adjuvant for seasonal influenza vaccine in elderly people: modelling immunogenicity from a randomized trial
Hans C. Rumke et al.
BMC INFECTIOUS DISEASES (2013)
Is Nursing Home Residence an Independent Predictor of Recurrent Hospitalization in Older Adults?
Tuen-Ching Chan et al.
JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION (2013)
Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5/Indonesia/05/2005) formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE plus GLA) adjuvant
John J. Treanor et al.
VACCINE (2013)
Assessment of Antigen-Specific and Cross-Reactive Antibody Responses to an MF59-Adjuvanted A/H5N1 Prepandemic Influenza Vaccine in Adult and Elderly Subjects
Ivan Bihari et al.
CLINICAL AND VACCINE IMMUNOLOGY (2012)
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Michael T. Osterholm et al.
LANCET INFECTIOUS DISEASES (2012)
Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine
Paul A. Tambyah et al.
VACCINE (2012)
Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: Homologous or heterologous booster response following two dose or single dose priming
Maikel V. W. van der Velden et al.
VACCINE (2012)
Safety and immunogenicity of an MF59®-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly
Timo Vesikari et al.
VACCINE (2012)
Immunogenicity Profile of a 3.75-μg Hemagglutinin Pandemic rH5N1 Split Virion AS03A-Adjuvanted Vaccine in Elderly Persons: A Randomized Trial
Stephane Heijmans et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
Subclinical Brain Injury Caused by H5N1 Influenza Virus Infection
Kyoko Shinya et al.
JOURNAL OF VIROLOGY (2011)
A Single-Dose Influenza A (H5N1) Vaccine Safe and Immunogenic in Adult and Elderly Patients: an Approach to Pandemic Vaccine Development
Zoltan Vajo et al.
JOURNAL OF VIROLOGY (2010)
Immunogenicity and adverse events of avian influenza A H5N1 vaccine in healthy adults: multiple-treatments meta-analysis
Lamberto Manzoli et al.
LANCET INFECTIOUS DISEASES (2009)
MF59®-Adjuvanted H5N1 Vaccine Induces Immunologic Memory and Heterotypic Antibody Responses in Non-Elderly and Elderly Adults
Angelika Banzhoff et al.
PLOS ONE (2009)
B cells and aging: molecules and mechanisms
Michael P. Cancro et al.
TRENDS IN IMMUNOLOGY (2009)
Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults
Wendy A. Keitel et al.
VACCINE (2009)
Humoral and cellular immune responses to split-virion H5N1 influenza vaccine in young and elderly adults
Isabel Leroux-Roels et al.
VACCINE (2009)
Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults
Rebecca C. Brady et al.
VACCINE (2009)
MF59®-adjuvanted vaccines for seasonal and pandemic influenza prophylaxis
Angelika Banzhoff et al.
INFLUENZA AND OTHER RESPIRATORY VIRUSES (2008)
Mortality benefits of influenza vaccination in elderly people: an ongoing controversy
Lone Simonsen et al.
LANCET INFECTIOUS DISEASES (2007)
Emergence and predominance of an H5N1 influenza variant in China
G. J. D. Smith et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine
JJ Treanor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Influenza-associated hospitalizations in the United States
WW Thompson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: Results from an immunogenicity meta-analysis
A Banzhoff et al.
GERONTOLOGY (2003)
Mortality associated with influenza and respiratory syncytial virus in the United States
WW Thompson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Outbreak of avian influenza A(H5N1) virus infection in Hong Kong in 1997
PKS Chan
CLINICAL INFECTIOUS DISEASES (2002)
Share Paper
